Boston Scientific Corp (BSX)vsIcecure Medical (ICCM)
BSX
Boston Scientific Corp
$42.98
-0.28%
HEALTHCARE · Cap: $62.29B
ICCM
Icecure Medical
$2.21
+3.27%
HEALTHCARE · Cap: $8.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 531848% more annual revenue ($21.00B vs $3.95M). BSX leads profitability with a 17.5% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 72/100 (B).
BSX
Strong Buy72
out of 100
Grade: B
ICCM
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$42.98
$3.91 premium
Intrinsic value data unavailable for ICCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Revenue surging 72.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : ICCM
The strongest argument for ICCM centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 72.8% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : ICCM
The primary concerns for ICCM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a mature stock while ICCM is a hypergrowth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.57 — expect wider price swings.
ICCM is growing revenue faster at 72.8% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 38/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Icecure Medical
HEALTHCARE · MEDICAL DEVICES · USA
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?